Today, 25% of patients that could benefit from proton therapy have moving tumors. However, as treating moving targets with confidence is a challenge, only 1% of those patients benefit from proton therapy today. To address motion management issues and bring back the best treatment options for proton therapy patients, IBA offers a comprehensive solution covering all aspects of motion management.